OOIR: Observatory of International Research

Papers

(The TQCC of Cytometry Part B-Clinical Cytometry is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Monitoring CAR T‐cells using flow cytometry	44
Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics	29
Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T‐cell clonality and diagnosis of T‐cell<	29
New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry	28
High‐sensitivity flow cytometric assays: Considerations for design control and analytical validation for identification of Rare events	26
Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping	24
Analysis of erythroid maturation in the nonlysed bone marrow with help of radar plots facilitates detection of flow cytometric aberrations in myelodysplastic syndromes	24
Monitoring CAR‐T cell kinetics in clinical trials by multiparametric flow cytometry: Benefits and challenges	21
A flow cytometric assay for HLA‐DR expression on monocytes validated as a biomarker for enrollment in sepsis clinical trials	20
Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses	20
CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab	20
Determination of CD43 and CD200 surface expression improves accuracy of B‐cell lymphoma immunophenotyping	19
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow	18
Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet	17
An easy and reliable whole blood freezing method for flow cytometry immuno‐phenotyping and functional analyses	16
Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26− or CD7−	15
ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry	14
Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact	14
Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry	13
Single‐cell profiling of pediatric T‐cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK–STAT signaling pathways	13
ESCCA/ISCCA protocol for the analysis of cerebrospinal fluid by multiparametric flow‐cytometry in hematological malignancies	13
Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry	13
Eleven‐marker 10‐color flow cytometric assessment of measurable residual disease for T‐cell acute lymphoblastic leukemia using an approach of exclusion	13
Platelet immunophenotyping in health and inherited bleeding disorders, a review and practical hints	12
Chimerism evaluation in measurable residual disease‐suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allog	12

Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by theELN iMDSflow working group	11
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis	11
Flow cytometric method transfer: Recommendations for best practice	11
Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes	11
New cytometry tools for immune monitoring during cancer immunotherapy	11
B‐lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting	11
14‐Color single tube for flow cytometric characterization of CD5+ B‐LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL	10
Increased TOX expression concurrent with PD‐1, Tim‐3, and CD244 expression in T cells from patients with acute myeloid leukemia	10
Performance of eight‐color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples	10
Exploring dyserythropoiesis in patients with myelodysplastic syndrome by imaging flow cytometry and machine‐learning assisted morphometrics	10
Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MD	10
Increased expression of immune checkpoint programmed cell death protein‐1 (PD‐1) on T cell subsets of bone marrow aspirates in patients with B‐Lymphoblastic leukemia, especially	10
Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes	10
Peripheral innate and adaptive immune cells during COVID‐19: Functional neutrophils, pro‐inflammatory monocytes, and half‐dead lymphocytes	10
Validation of a modified pre‐lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B‐non Hodgkin lymphoma	10
Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through ass	9
The utility of flow cytometry in the diagnostic work up of malignant effusions due to nonhematopoietic neoplasms	9
Immunophenotypic shift in the B‐cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B‐lymphoblastic leukemia	9
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues	9
Illuminating the immunopathology of SARS‐CoV‐2	9
A multicenter study evaluation of the ClearLLab 10C panels	8
Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry	8
Relevance of polyclonal plasma cells and post‐therapy immunomodulation in measurable residual disease assessment in multiple myeloma	8
Characterization of KIR + NKG2A + Eomes− NK‐like CD8+ T cells and their decline with age in healthy individuals	8
Leukocyte immunoglobulin‐like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation	8
FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study	8
Clinical and laboratory features associated with myeloperoxidase expression in pediatric B‐lymphoblastic leukemia	8
Development and validation of a high‐parameter mass cytometry workflow to decipher immunomodulatory changes in celiac disease	7
The ISCCA flow protocol for the monitoring of anti‐CD20 therapies in autoimmune disorders	7
International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality moni	7
The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes	7
Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy	7
Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse larg	7
Characteristic CD45RA/CD45RO maturation pattern by flow cytometry associated with the CD45 C77G polymorphism	7
Utility of CD36 as a novel addition to the immunophenotypic signature of RAM‐phenotype acute myeloid leukemia and study of its clinicopathological characteristics	7
Steric hindrance: A practical (and frequently forgotten) problem in flow cytometry	7
Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single‐institution experience	6
A rare biclonal Hairy Cell Leukemia disclosed by an integrated diagnostic approach: A case report	6
Machine learning optimized multiparameter radar plots for B‐cell acute lymphoblastic leukemia minimal residual disease analysis	6
Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern‐based recognition	6
Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples	6
Bicentric evaluation of stabilizing sampling tubes for assessment of monocyte HLA‐DR expression in clinical samples	6
Flow cytometry‐based analysis of tumor‐leukocyte ratios in peritoneal fluid from patients with advanced gastric cancer	6
Evaluation of B‐cell intracellular signaling by monitoring the PI3K‐Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3‐kinase delta syndrome	5
Use of flow cytometry and cytology to differentiate breast implant‐associated anaplastic large cell lymphoma from reactive seromas in Brazilian patients	5
Resolving 31 colors on a standard 3‐laser full spectrum flow cytometer for immune monitoring of human blood samples	5
Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR‐ABL1, KMT2A rearrangement, and other adult B‐cell precursor	5
Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review	5
Validation of inducible basophil biomarkers: Time, temperature and transportation	5
Best practices for optimization and validation of flow cytometry‐based receptor occupancy assays	5

PD‐1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome	5
Analysis of human chromosomes by imaging flow cytometry	5
Validation of a new multiparametric protocol to assess viability, acrosome integrity and mitochondrial activity in cooled and frozen thawed boar spermatozoa	5
Refractory neutrophils and monocytes in patients with inflammatory bowel disease after repeated bouts of prolonged exercise	5
Detection of CAR‐T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories	5
Sudden blast phase in pediatric chronic myeloid leukemia‐chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign?	5
Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy	5
Diagnostic performance of the ClearLLab 10C B cell tube	5
Flow cytometry immunophenotypic features of pure erythroid leukemia and the distinction from reactive erythroid precursors	5